Reporter brief
Δ133p53α transgene reduces CXCL10 in progeria and naturally aged mice, preclinical study
What happened
This preclinical study examined whether transgenic expression of Δ133p53α, a senescence-inhibitory p53 isoform, alters inflammatory cytokines and chemokines in aging mice. Δ133p53α-expressing transgenic mice (both progeria model and naturally aged wild-type) showed reduced serum and tissue CXCL10 levels compared to controls, along with reductions in IL-6, CXCL1, and IL-1α. An inverse association between CXCL10 and Δ133p53α levels was also observed in human spleen tissue samples.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Preclinical; Animal.
Transgenic Δ133p53α-expressing Lmna G609G/+ progeria model mice (young 15-week-old and old 10-month-old), naturally aged wild-type mice (2 years old), and human spleen tissue samples
- Design
- Preclinical
- Sample
- —
- Journal
- Geromedicine
- Published
- Jan 1, 2026
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Partial cellular reprogramming timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.